Male sexual dysfunction — encompassing erectile dysfunction (ED), reduced libido, and impaired sexual performance — affects an estimated 52% of men between 40 and 70 years of age. While PDE5 inhibitors (Viagra, Cialis) have dominated the treatment landscape for decades, they address only the vascular component of erectile function. PT-141 (Bremelanotide) targets the neurological and psychological components through a completely different mechanism.
The Central Mechanism
PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus — the brain regions responsible for initiating sexual arousal and desire. Unlike PDE5 inhibitors, which work downstream on vascular smooth muscle to facilitate blood flow once arousal has already occurred, PT-141 works upstream to initiate the neurological cascade that drives sexual desire in the first place.
Complementary to PDE5 Inhibitors
For men with psychogenic ED — where the primary issue is reduced desire or arousal rather than vascular insufficiency — PT-141 addresses the root cause that PDE5 inhibitors cannot. For men with mixed ED (both vascular and psychogenic components), PT-141 and PDE5 inhibitors can be used together for a comprehensive approach.
Clinical Evidence
Multiple Phase II and III clinical trials have demonstrated PT-141's efficacy in men with ED, including those who had failed PDE5 inhibitor therapy. The compound received FDA approval as Bremelanotide (Vyleesi) for female HSDD, with robust off-label use in men supported by clinical evidence.